Protopic

DRUG3 trials

Sponsors

LifeCycle Pharma A/S, Astellas Pharma Inc, Centre Hospitalier Universitaire de Nice

Conditions

Dermatitis, AtopicLCP-Tacro tablets will be investigated for immunosuppression for the prevention of acute allograft rejection in adult renal transplant patients. MedDRA version: 9.1 Level: LLT Classification code 10048870 Term: Prophylaxis against transplant rejectionPigmentation DisordersVitiligo

Phase 2

Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control

TerminatedNCT01841008

Centre Hospitalier Universitaire de NicePigmentation Disorders, Vitiligo

Start: 2011-12-31End: 2014-06-30Updated: 2014-09-05

Phase 4

A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis

CompletedNCT00106496

Astellas Pharma IncDermatitis, Atopic

Start: 2004-10-31End: 2006-07-31Updated: 2014-09-18

Unknown Phase

A Phase 3, Open-label, Multicenter, Prospective, Randomized Study of the Efficacy and Safety of Conversion from Prograf® Capsules Twice Daily to LCP-Tacro™ Tablets Once Daily for the Prevention of Acute Allograft Rejection in Stable Kidney Transplant Patients

Active, not recruitingEUCTR2008-003240-11-DE

LifeCycle Pharma A/SLCP-Tacro tablets will be investigated for immunosuppression for the prevention of acute allograft rejection in adult renal transplant patients. MedDRA version: 9.1 Level: LLT Classification code 10048870 Term: Prophylaxis against transplant rejection

Start: 2009-02-25Target: 302Updated: 2012-04-24